HIV-1 integrase inhibitors: a comparative review of efficacy and safety
KK Scarsi, JP Havens, AT Podany, SN Avedissian… - Drugs, 2020 - Springer
The newest class of antiretrovirals for all persons living with HIV are the integrase strand
transfer inhibitors (INSTIs). Since 2007, five INSTIs have been introduced: raltegravir …
transfer inhibitors (INSTIs). Since 2007, five INSTIs have been introduced: raltegravir …
Clinical pharmacology in HIV therapy
The success of combination antiretroviral therapy in the treatment of HIV-1–positive
individuals has shifted clinical attention toward combination antiretroviral drug regimens that …
individuals has shifted clinical attention toward combination antiretroviral drug regimens that …
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society–USA panel
Context New trial data and drug regimens that have become available in the last 2 years
warrant an update to guidelines for antiretroviral therapy (ART) in human immunodeficiency …
warrant an update to guidelines for antiretroviral therapy (ART) in human immunodeficiency …
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non …
P Cahn, AL Pozniak, H Mingrone, A Shuldyakov… - The Lancet, 2013 - thelancet.com
Summary Background Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has
shown potent antiviral response and a favourable safety profile. We evaluated safety …
shown potent antiviral response and a favourable safety profile. We evaluated safety …
Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials
JB Nachega, JJ Parienti, OA Uthman… - Clinical infectious …, 2014 - academic.oup.com
Background. Contemporary antiretroviral treatment regimens are simpler than in the past,
with lower pill burden and once-daily dosing frequency common. We performed a meta …
with lower pill burden and once-daily dosing frequency common. We performed a meta …
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double …
F Raffi, H Jaeger, E Quiros-Roldan… - The Lancet infectious …, 2013 - thelancet.com
Background In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-
inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive …
inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive …
British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in …
Writing Group, I Williams, D Churchill… - HIV …, 2014 - Wiley Online Library
1.4 Resource use 1.5 Implications for research 1.6 References 2.0 Recommendations and
auditable outcomes 2.1 Recommendations (GRADE) 2.1. 1 Patient involvement in decision …
auditable outcomes 2.1 Recommendations (GRADE) 2.1. 1 Patient involvement in decision …
Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 …
KE Dooley, P Sayre, J Borland, E Purdy… - JAIDS Journal of …, 2013 - journals.lww.com
Background: Cotreatment of tuberculosis (TB) and HIV among coinfected patients is now the
standard of care. Rifampin (RIF) is a standard part of TB treatment but is a potent inducer of …
standard of care. Rifampin (RIF) is a standard part of TB treatment but is a potent inducer of …
Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study
HJ Stellbrink, J Reynes, A Lazzarin, E Voronin… - Aids, 2013 - journals.lww.com
Objective: To evaluate the efficacy and safety/tolerability of dolutegravir (DTG,
S/GSK1349572), a potent inhibitor of HIV integrase, through the full 96 weeks of the SPRING …
S/GSK1349572), a potent inhibitor of HIV integrase, through the full 96 weeks of the SPRING …
Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors
AT Podany, KK Scarsi, CV Fletcher - Clinical pharmacokinetics, 2017 - Springer
Abstract Dolutegravir (DTG), elvitegravir (EVG) and raltegravir (RAL) are members of the
latest class of antiretrovirals (ARVs) that have become available to treat human …
latest class of antiretrovirals (ARVs) that have become available to treat human …